1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
223.30%
Cash & equivalents growing 223.30% while Drug Manufacturers - Specialty & Generic shows decline of -2.01%. Warren Buffett would see this as a competitive advantage in maintaining liquidity while peers face cash constraints.
No Data
No Data available this quarter, please select a different quarter.
223.30%
Cash + STI yoy growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
17.78%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
30.20%
Inventory growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.32%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
-28.22%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
172.72%
Below half the Drug Manufacturers - Specialty & Generic median of -0.21%. Jim Chanos would question if the company faces working capital strain.
80.24%
PP&E growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
-0.37%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
25.61%
Intangibles growth < half the Drug Manufacturers - Specialty & Generic median of -0.13%. Joel Greenblatt sees fewer intangible expansions vs. peers. Possibly less impairment risk.
19.96%
Below half of Drug Manufacturers - Specialty & Generic median of -0.00%. Joel Greenblatt sees relatively minimal intangible expansions vs. peers.
71.47%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
56.17%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.16%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
126.50%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
110.82%
Payables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.81%. Jim Chanos might see a warning sign of stressed supplier payments.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
168.40%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.42%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
718.69%
Below half Drug Manufacturers - Specialty & Generic median of -1.68%. Joel Greenblatt sees a much lower liability expansion vs. peers.
87.62%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
11.09%
Below half Drug Manufacturers - Specialty & Generic median of -0.18%. Jim Chanos suspects poor profitability or large dividend drains.
No Data
No Data available this quarter, please select a different quarter.
0.79%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
105.08%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 1.41%. Joel Greenblatt sees stronger equity growth vs. peers.
126.50%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees more aggressive expansions than peers.
71.47%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-176.56%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.
